Open company graph database — free web & API
Login

Shionogi Techno Advance Research Inc.

シオノギテクノアドバンスリサーチ株式会社Shionogi TechnoAdvance Research CO., LTD.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
209
Related companies
11
§01

Basic information

BASIC
Head office
3-1-1 Futabacho, Toyonaka, Osaka 561-0825, Japan
Chief executive
Jun Yoshimoto
Capital
9,000,000 JPY
Employees (non-consolidated)
Employees (consolidated)
209 people
Start date
2010-09-08
End date
§02

Websites

1 DOMAINS
§03

Business

5
Compound synthesis, purification, and managementTest material preparationAnimal production, supply, and breeding managementIn vitro/in vivo testing, inspection, and analysisResearch management and support services
§04

Related companies

11 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Shionogi Inc.
Group Parent
Shionogi & Co., Ltd.
Group Parent Customer
Shionogi Business Partner Co., Ltd.
Group
Beijing Shionogi Pharmaceutical Technology Limited
Group
UMN Pharma Co., Ltd.
Group
Suntory
Group
Shionogi Smile Heart
Group
Shionogi キャリア開発センター株式会社
Group
Shionogi ファーマ
Group
Asahi Group Japan subsidiary, Asahi Beverage Co., Ltd.
Supplier
Oil Japan Agro Research Co., Ltd.
Supplier
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

20 EVENTS

On March 17, 1878, on his 24th birthday, he became independent and founded the drugstore 'Shiono Gisaburo Shoten' at 3-12 Doshomachi, Osaka.Sources

Initially dealing mainly with Japanese and Chinese medicines, in 1886, eight years after founding, Western medicine began to be imported and sold as Western medicine became widely popular.Sources

Antadizin was the first new drug developed in-house by Shiono Gisaburo Shoten, marking a milestone as the company's first original drug.Sources

Trademark registration of the Fudan mark, based on the pursuit of accuracy.Sources

Construction of the Shiono Pharmaceutical Plant for new drugs and manufacturing.Sources

In 1919, the year after the end of World War II, to further develop SHIONOGI, the drugstore 'Shiono Gisaburo Shoten' managed by Gizo Saburo's eldest son, Shota, and the pharmaceutical business 'Shiono Pharmaceutical Plant' run by his second son, Chojiro, merged to establish 'Shiono Gishodo Co., Ltd.'.Sources

Changed the company name to Shiono Gishodo Pharmaceutical Co., Ltd.Sources

Due to rapid inflation after the war, soaring prices, and economic chaos, SHIONOGI faced near bankruptcy and fell into its worst management condition since its founding, with frozen corporate deposits and the termination of wartime compensation.Sources

In 1948, the company set three major goals ('Raising all technologies, thorough goal setting and confirmation, and beautification') to overcome the crisis and started efforts to improve management.Sources

Launch of the analgesic drug 'Sedres'Sources

First, to consolidate into the pharmaceutical business, we transferred and transferred the sales of plant drugs, animal drugs, and pharmaceutical wholesalers to other companies. In addition, aiming to narrow down research areas and speed up development, we established a development subsidiary in the United States in 2001, and further started joint development of new drugs through a partnership with GlaxoSmithKline in the UK.Sources

In 2001, a development subsidiary was established in the United States.Sources

In 2011, we acquired Chinese pharmaceutical company C&O Pharmaceutical Technology (Holdings) Limited.Sources

In 2012, a development subsidiary, Shionogi Limited, was established in the UK.Sources

From April 2014 (Heisei 26), the new mid-term management plan set a vision to 'grow as a drug discovery-oriented pharmaceutical company,' and established ROE (Return on Equity) as one of the management indicators. It clarified the items to be achieved over the past three years, and clearly indicated efforts toward the management goals for 2020, while confirming results and issues annually in a rolling manner.Sources

Establishment of a joint venture with Shimadzu Corporation, 'AdvanSentinel Inc.'Sources

Establishment of the general incorporated foundation, 'Shionogi Infectious Disease Research Promotion Foundation'Sources

Development of the SHIONOGI group brand and the establishment of the group brand markSources

Establishment of Yui Connection Inc.Sources

Launch of the new coronavirus infection treatment drug 'Zocova'Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information5120901029897
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
シオノギテクノアドバンスリサーチ株式会社
Trade name (kana)
シオノギテクノアドバンスリサーチ
Name in English
Corporation type
301
Address
〒561-0825 大阪府豊中市二葉町3丁目1番1号
Postal code
5610825
Prefecture code
27
City code
203
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-04-23
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
4238551
METI gBizINFO5120901029897
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
5120901029897
Trade name
シオノギテクノアドバンスリサーチ株式会社
Trade name (kana)
シオノギテクノアドバンスリサーチ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
大阪府豊中市二葉町3丁目1番1号
Postal code
5610825
Prefecture
大阪府
Prefecture code
27
City or district
豊中市
City code
203
Street address
二葉町3丁目1番1号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
Capital
Employees
230
Employees (male)
110
Employees (female)
120
Business summary
実験系研究支援受託業
Website URL
http://www.shionogi-tar.co.jp/
Year founded
Business category
L:学術研究、専門・技術サービス業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-04-23
Key information
5120901029897
§09

Sources & updates

SOURCES
↑